Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART
Authors:
- 27 November 2009
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 23 (18) , 2451-2458
Abstract
Design: Rabies vaccine was used as a T-cell-dependent neoantigen to investigate several aspects of the primary and booster immune response in vivo in HIV-infected individuals receiving antiretroviral treatment. Methods: Study participants received rabies vaccination twice, within a 3-month interval. Serum samples were taken before and 1, 2 and 4 weeks after both vaccinations and 1 and 5 years after the primary vaccination. Antirabies antibodies [immunoglobulin G (IgG), IgG subclasses, immunoglobulin A (IgA) and immunoglobulin M (IgM)] were determined; antibody avidity was measured after both vaccinations. T-cell subsets were characterized by flow cytometry. Results: Eighteen healthy controls and 30 HIV-infected adults, treated with HAART for almost 4 years, with a median CD4+ T-cell count of 537 cells/μl, were immunized. The postvaccination concentrations of antirabies IgG and IgM were significantly lower in HIV-infected individuals as compared with controls. Three T-cell-dependent processes, a true booster response, a class switch from IgM to IgG and avidity maturation were present in both healthy controls and HIV-infected individuals. Higher age was associated with lower postvaccination antirabies IgG and IgM titers. Five years after the primary vaccination, 63% of the HIV-infected individuals still had antibody titers above the protection threshold. Conclusion: Immune restoration in HIV-infected individuals treated with HAART, resulting in a CD4+ T-cell count greater than 500 cells/μl, is incomplete. However, the majority of HIV-infected individuals are capable of mounting a long-lasting immune response, including several pivotal T-cell-dependent processes, upon vaccination with a neoantigen such as the rabies vaccine.Keywords
This publication has 47 references indexed in Scilit:
- Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individualsJournal of Experimental Medicine, 2008
- Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudyClinical and Experimental Immunology, 2008
- Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionNature Medicine, 2006
- Determinants of CD4+T Cell Recovery during Suppressive Antiretroviral Therapy: Association of Immune Activation, T Cell Maturation Markers, and Cellular HIV‐1 DNAThe Journal of Infectious Diseases, 2006
- Naïve T-Cell Dynamics in Human Immunodeficiency Virus Type 1 Infection: Effects of Highly Active Antiretroviral Therapy Provide Insights into the Mechanisms of Naïve T-Cell DepletionJournal of Virology, 2006
- Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infectionHIV Medicine, 2004
- Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohortJournal of Adolescent Health, 2001
- Effect of Highly Active Antiretroviral Therapy on the Serological Response to Additional Measles Vaccinations in Human Immunodeficiency Virus-Infected ChildrenClinical Infectious Diseases, 2001
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998